What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

2013/12/10 by Robert L Avery, Robert L. Avery · 26 citations
Medicine · #Retinal Diseases and Treatments #Retinopathy of Prematurity Studies #Retinal and Optic Conditions

paper · pdf · doi:10.1136/bjophthalmol-2013-303844

Abstract

Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance of these systemic effects remains unclear, but further study is indicated.

Cited by

• Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
• Introduction. Treatment paradigms within the use of anti-VEGF agents. [europepmc]
• The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells. [europepmc]
• Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. [europepmc]
• Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study. [europepmc]
• Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept. [europepmc]
• Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin. [europepmc]
• Early management of sight threatening retinopathy in incontinentia pigmenti. [europepmc]
• Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use. [europepmc]
• TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands. [europepmc]
• Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. [europepmc]
• Transient Ischemic Attack and Hypoventilation 12 Hours After Intra-vitreal Aflibercept Injection. [europepmc]
• Effects of Hypoxic Preconditioning and Vascular Endothelial Growth Factor on the Survival of Isolated Primary Retinal Ganglion Cells. [europepmc]
• Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. [europepmc]
• Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years. [europepmc]
• Research Advances in Age-Related Macular Degeneration. [europepmc]
• The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients. [europepmc]
• Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network. [europepmc]
• End binding-3 inhibitor activates regenerative program in age-related macular degeneration. [europepmc]
• Next generation therapeutics for retinal neurodegenerative diseases. [europepmc]
• Cardiovascular diseases in patients with cancer: A comprehensive review of epidemiological trends, cardiac complications, and prognostic implications. [europepmc]
• Intravitreal therapy-success stories and challenges. [europepmc]
• CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study. [europepmc]
• Collaborative care for pregnant women with eye conditions. [europepmc]
• Ophthalmic conditions affecting the choroid and retina in pregnancy: An overview of key pathologies. [europepmc]
• Anti-VEGF safety in evolution: A comprehensive review of ocular and systemic considerations. [europepmc]

Related

• Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?
• Anti-VEGF injections and macular atrophy progression in patients with neovascular age-related macular degeneration in remission
• Choroidal thickness after anti-vascular endothelial growth factor in typical neovascular age-related macular degeneration – A systematic review and meta-analysis
• Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells
• Visually Predictive Biomarkers on OCT & OCTA following Anti-VEGF treatment of RVO